Showing 1 - 8 results of 8 for search 'Nastya Kassir', query time: 0.03s Refine Results
  1. 1
    Machine Learning for Exposure-Response Analysis: Methodological Considerations and Confirmation of Their Importance via Computational Experimentations

    Machine Learning for Exposure-Response Analysis: Methodological Considerations and Confirmation of Their Importance via Computational Experimentations by Rashed Harun, Eric Yang, Nastya Kassir, Wenhui Zhang, James Lu

    Published 2023-04-01
    Get full text
    Article
  2. 2
    A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score

    A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score by Anita Moein, Jurgen Langenhorst, Elodie L. Plan, Jin Y. Jin, Matts Kågedal, Nastya Kassir

    Published 2023-11-01
    Get full text
    Article
  3. 3
    Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib

    Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib by Christine Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Nastya Kassir, Yuan Chen

    Published 2024-04-01
    Get full text
    Article
  4. 4
    Predicting overall survival from tumor dynamics metrics using parametric statistical and machine learning models: application to patients with RET-altered solid tumors

    Predicting overall survival from tumor dynamics metrics using parametric statistical and machine learning models: application to patients with RET-altered solid tumors by Erick Velasquez, Nastya Kassir, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Steve Dang, Dale Miles, James Lu

    Published 2024-06-01
    Get full text
    Article
  5. 5
    Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis

    Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis by Nastya Kassir, Rui Zhu, Anita Moein, Jurgen Langenhorst, Jakob Ribbing, Rong Zhang, Meina T. Tang, Young S. Oh, Wenhui Zhang

    Published 2022-09-01
    Get full text
    Article
  6. 6
    Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis

    Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis by Anita Moein, Tong Lu, Siv Jönsson, Jakob Ribbing, Nastya Kassir, Wenhui Zhang, Gizette Sperinde, Rong Zhang, Meina Tang, Young S. Oh, Rene Bruno, Rui Zhu

    Published 2022-09-01
    Get full text
    Article
  7. 7
    Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes

    Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes by Nianhang Chen, Nastya Kassir, Abderrahmane Laadem, Stephen E. Maxwell, Priya Sriraman, Ana Carolina Giuseppi, Steve Ritland, Peter G. Linde, Balasubrahmanyam Budda, Joseph G. Reynolds, Simon Zhou, Maria Palmisano

    Published 2020-07-01
    Get full text
    Article
  8. 8
    Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study

    Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study by Khalil Ben Hassine, Tiago Nava, Yves Théoret, Christa E. Nath, Youssef Daali, Nastya Kassir, Victor Lewis, Robbert G. M. Bredius, Peter J. Shaw, Henrique Bittencourt, Maja Krajinovic, Chakradhara Rao Satyanarayana Uppugunduri, Marc Ansari

    Published 2021-09-01
    Get full text
    Article

Search Tools: